CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study

Nov 14, 2017
By Applied Clinical Trials Editors

CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers. 

Read the full release here.

lorem ipsum